In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Hold rating on Strata Skin Sciences (SSKN – Research Report). The company’s shares closed last Monday at $0.84, close to its 52-week low of $0.76.
According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -7.7% and a 27.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.
Currently, the analyst consensus on Strata Skin Sciences is a Moderate Buy with an average price target of $6.00.
Based on Strata Skin Sciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $8.9 million and GAAP net loss of $515K. In comparison, last year the company earned revenue of $8 million and had a net profit of $285K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
STRATA Skin Sciences, Inc. is a medical technology company. The firm engages in the design, development, and commercializing of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations. It operates through the following segments: Dermatology Recurring Procedures; Dermatology Procedures Equipment; and Dermatology Imaging. The Dermatology Recurring Procedures segment offers XTRAC procedures. The Dermatology Procedures Equipment segment sells lasers and lamp products. The Dermatology Imaging segment comprises of the retail and usage of imaging devices. The company was founded by Dina Gutkowicz-Krusin in December 1989 and is headquartered in Horsham, PA.